Archive: Company News
— FDA grants RPDD for the treatment of Duchenne muscular dystrophy (DMD)
— MetrioPharm may be eligible for a priority review voucher with a market value in excess of USD 100 million
— MetrioPharm has recently raised CHF 18 million for the development of MP1032 in DMD in a Series D round and is targeting a second closing
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.